CoChat

Diagnosis of Gestational Diabetes Mellitus Will Be Flawed until We Can Measure Glucose

Open access
Bruns, David E, Metzger, Boyd E, Sacks, David B · 2020 · Clinical Chemistry

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Gestational diabetes mellitus (GDM) is defined by glucose intolerance that is first documented during pregnancy (1,). Maternal hyperglycemia that is less severe than that in diabetes mellitus is strongly associated with increased birth weight, risk of Caesarean delivery, and other adverse outcomes (2,). Diagnosis of GDM is important because the risk of adverse events is reduced by treatment (3, 4). Diagnosis of GDM depends exclusively on measurements of plasma glucose. Glucose is typically measured before and at fixed time points after an oral glucose load (5,). However, a diagnosis of GDM often is made or excluded based on a single measured glucose concentration above or below a defined threshold (6,). By contrast, outside of pregnancy, diagnosis of diabetes requires, in the absence of typical symptoms, documentation of hyperglycemia (by either glucose or hemoglobin A1c) on more than one occasion (7). The requirement for accurate glucose measurements for diagnosis of GDM is heightened by the fact that hemoglobin A1c is not an alternative to glucose measurements for diagnosis of GDM. A major source of preanalytical error in measuring glucose is loss of glucose from blood specimens through glycolysis occurring primarily in red and white blood cells (8,). Glucose is lost from whole blood samples at a rate of 5%–7% per hour at room temperature (8). Thus, loss of glucose at 1 h exceeds the desirable limit of total analytical error for glucose based on biological variation. This preanalytical loss of glucose poses a threat to the diagnostic sensitivity of testing for GDM. Moreover, variation in time to centrifugation of blood samples introduces variability in glucose results with resultant variability in likelihood of diagnosis of GDM. Sodium fluoride (NaF) is widely used to inhibit glycolysis, but it is inadequate. NaF does not stop glycolysis for the first 2 h or more after sample collection, and during the first 60–90 min the loss of glucose proceeds at the same rate with or without NaF (8, 9,). Glucose tolerance testing presents a special problem when the fasting and other samples are held at the point of care (POC) for ≥2 h until completion of the procedure (10). The AACC and American Diabetes Association (ADA) guideline on laboratory testing in diabetes (8,) addresses the handling of samples collected for measurement of glucose in the diagnosis of diabetes. The guideline recommends that samples be immediately immersed in an ice slurry and analyzed within 30 min of collection (8,). This is difficult to achieve in routine patient care, and evidence suggests that this recommendation is not always followed in testing for GDM (10, 11). A study in this issue of Clinical Chemistry addresses the problem that glycolysis presents in the diagnosis of GDM (12,). In a previous study (10,), some of the same authors compared results of GDM testing in which samples were handled either with their institution’s usual procedures, including use of NaF-containing blood tubes, or according to the ADA/AACC-recommended procedures (8,). The recommended sample-handling approach produced a 2.7-fold increase in the rate of diagnosis of GDM (10). The increase was entirely attributable to control of glycolysis. Now these authors have evaluated the potential of glucose meters, used at the point of care, to improve the diagnostic accuracy of testing for GDM by minimizing the loss of glucose before analysis (12,). Thus, they measured glucose in skin-puncture blood at the POC, with samples collected from patients in the fasting state and at 1 and 2 h after a 75-gram oral glucose load. Venous blood samples were collected at the same times, and handled strictly according the ADA/AACC guidelines; glucose in the venous plasma was measured in a laboratory nationally accredited according to ISO 15189. Linear regression analysis of the POC glucose results vs. the laboratory plasma glucose results was conducted using a randomly selected derivation cohort (n = 102). The resulting equations were used to calculate the predicted laboratory plasma glucose result corresponding to each POC capillary result in the remainder of the cohort (n = 100). For estimation of diagnostic accuracy of the glucose meters in the latter cohort, the predicted venous values were used rather than the actual meter results. For the reference standard for diagnosis of GDM, the authors used the glucose concentrations in the venous plasma samples. For both types of samples the same diagnostic criteria (6) were used. The diagnostic accuracy with the predicted venous plasma results was not as good as might be hoped: The diagnostic sensitivity was 80.4% (95% CI 67.6–89.8) and the diagnostic specificity was 86.4% (72.7–94.8). The positive and negative likelihood ratios for predicting a diagnosis of GDM (made by the reference standard) can be calculated to be 5.9 and 0.23, respectively, corresponding to moderate changes in post-test probability of GDM. The authors concluded that the

Overview

Integrity signals

Registry

Crossref · 10.1093/clinchem/hvz027

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Cited by

See all 31

Metadata

Authors
Bruns, D. E., Metzger, B. E., & Sacks, D. B.
Affiliations
  • University of Virginia (US)
  • Northwestern University (US)
  • National Institutes of Health (US)
Corresponding author
Bruns, David E
Venue
Clinical Chemistry
Published
2020-02-01
Volume
66
Issue
2
Pages
265-267
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W3006574392
Cited by
30
References
16
Citations by year
2025: 4 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 3 · 2020: 6
Type
journal article
Language
en
Open access
Locations
  • Clinical Chemistry (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Intramural Research Program
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
Keywords
gestational diabetes mellitus, glucose measurement, pre-analytical errors, glycolysis, blood sample storage, sodium fluoride, point-of-care testing, glucose tolerance test, HbA1c, diagnostic sensitivity, sample handling, diagnostic thresholds, oral glucose tolerance test, gestational weight gain, maternal hyperglycemia
MeSH terms
Blood Glucose, Female, Glucose, Glucose Tolerance Test, Humans, Pregnancy, Prospective Studies, Diabetes, Gestational, Point-of-Care Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis of Gestational Diabetes Mellitus Will Be Flawed until We Can Measure Glucose. https://app.cochat.ai/papers/10.1093/clinchem/hvz027
The paper
Bruns, D. E., Metzger, B. E., & Sacks, D. B. (2020). Diagnosis of Gestational Diabetes Mellitus Will Be Flawed until We Can Measure Glucose. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvz027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.